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Abstract
Cessation of chronic ethanol consumption can increase the sensitivity of the brain to excitotoxic damages. Cannabinoids
have been proposed as neuroprotectants in different models of neuronal injury, but their effect have never been
investigated in a context of excitotoxicity after alcohol cessation. Here we examined the effects of the pharmacological
activation/inhibition of the endocannabinoid system in an in vitro model of chronic ethanol exposure and withdrawal
followed by an excitotoxic challenge. Ethanol withdrawal increased N-methyl-D-aspartate (NMDA)-evoked neuronal death,
probably by altering the ratio between GluN2A and GluN2B NMDA receptor subunits. The stimulation of the
endocannabinoid system with the cannabinoid agonist HU-210 decreased NMDA-induced neuronal death exclusively in
ethanol-withdrawn neurons. This neuroprotection could be explained by a decrease in NMDA-stimulated calcium influx
after the administration of HU-210, found exclusively in ethanol-withdrawn neurons. By contrast, the inhibition of the
cannabinoid system with the CB1 receptor antagonist rimonabant (SR141716) during ethanol withdrawal increased death of
ethanol-withdrawn neurons without any modification of NMDA-stimulated calcium influx. Moreover, chronic administration
of rimonabant increased NMDA-stimulated toxicity not only in withdrawn neurons, but also in control neurons. In summary,
we show for the first time that the stimulation of the endocannabinoid system is protective against the hyperexcitability
developed during alcohol withdrawal. By contrast, the blockade of the endocannabinoid system is highly counterproductive
during alcohol withdrawal.
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Introduction
Continued excessive ethanol consumption can lead to the
development of dependence that is associated with a withdrawal
syndrome when ethanol consumption is interrupted or substan-
tially reduced. This syndrome comprises psychological symptoms
that contribute to distress and psychological discomfort, as well as
physical signs that include tremor, agitation, delirium and in
severe cases, convulsions and brain damages [1]. Neuroadaptive
changes during ethanol consumption are believed to play an
important role in the development of tolerance and physical
dependence to ethanol. The alterations in glutamatergic trans-
mission observed after ethanol exposure seem to play a key role in
these responses, and could bring the brain to a hyperexcitable state
[2].
Classical pharmacotherapies for treating alcohol-dependent
subjects are addressed to reduce craving and early withdrawal
symptoms (tremor, agitation, delirium), but they do not provide
direct beneficial effects on the occurrence of brain damages, one of
the major long-term consequences of alcohol dependence.
Therefore, the search of novel compounds able to protect the
brain against the degenerative events associated with alcohol
dependence and withdrawal is a key objective, then concurring
with the efforts for developing protective drugs for the treatment of
acute or chronic neurodegenerative disorders. In this context,
there is large evidence that cannabinoid agonists exert neuropro-
tection in several models of neuronal injury [3]. The mechanisms
of this neuroprotection include, among others: (i) inhibition of
excitatory glutamatergic transmission through presynaptic CB1
receptors [4–6]; and (ii) modulation of neuronal excitability
exerted through the control of calcium (inhibition of voltage-
dependent and other types of calcium channels) and potassium
(activation of inwardly rectifying potassium channels) conductanc-
es [7]. These properties have been tested in multiple pathological
conditions (e.g. hypoxia-ischemia, brain trauma, Parkinson’s
disease, Huntington’s chorea), but never in an alcohol withdrawal
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23690situation. In this study, we wanted to test if cannabinoids could
influence neurotoxicity during ethanol withdrawal. Besides, it has
been described that CB1 receptor-deficient mice do not develop
the changes in N-methyl-D-aspartate (NMDA) and c-amino
butyric acid (GABA)A receptors observed in wild-type animals
[8], suggesting that the endocannabinoid system may be
implicated in the development of these glutamatergic and
GABAergic neuroadaptations during chronic ethanol exposure.
Accordingly, it would be of a great interest to examine whether the
pharmacological activation or inhibition of the endocannabinoid
system affects alcohol withdrawal-induced hypersensitivity to
excitotoxic insults. To do this, we designed a series of experiments
in an in vitro model of cultured murine cortical neurons to
determine the changes in neuronal survival caused by the
activation or the inhibition of the endocannabinoid signaling in
conditions of chronic ethanol consumption and withdrawal.
Experiments were conducted in basal conditions or after an
excitotoxic stimulus with NMDA. In order to find the molecular
bases of the effects found in the pharmacological experiments, we
studied the changes in calcium influx and the expression of specific
subunits of NMDA receptors.
Results
Ethanol withdrawal increases by 40% the sensitivity of
neurons to excitotoxic injuries
We developed an in vitro model of ethanol withdrawal which
consisted in a chronic ethanol administration (100 mM, 3 days)
and subsequent withdrawal (2 days), based on the model
described by Nagy et al. [9]. Neuronal death was slightly
increased in ethanol-withdrawn neurons (+10% cell death,
P,0.05; figure 1B). In addition, we observed a significant
increase in NMDA-stimulated cell death in ethanol-withdrawn
neurons (+40% versus NMDA-treated control neurons; P,0.001;
figure 1B) compared to NMDA-treated control (not exposed to
ethanol) neurons, indicating that ethanol withdrawal renders
neurons more sensitive to excitotoxic challenges. Representative
phase-contrast photomicrographs under the indicated conditions
are shown in figure 1A.
Ethanol withdrawal decreases GluN2A subunit levels
In order to determine the origin of the increased sensitivity to
NMDA-induced cell death in ethanol-withdrawn neurons, we
examined the expression of the main NMDA receptor subunits,
i.e., GluN1, GluN2A and GluN2B. GluN2A subunit expression,
measured by quantitative real time RT-PCR (qRT-PCR), was
significantly decreased in the withdrawal situation (P,0.05). No
changes were observed for GluN1 or GluN2B subunit expression
levels (table 1). Besides, we wanted to evaluate the possible changes
after chronic ethanol administration in two important elements of
the endocannabinoid system that have been related to alcohol
addiction: CB1 receptors and fatty acid amide hydrolase (FAAH)
levels [10]. CB1 receptor mRNA levels tended to increase after
ethanol exposure and subsequent withdrawal, but this increase did
not reach statistical significance (p=0.098). The levels of FAAH
enzyme remained unaffected.
To confirm the changes in mRNA expression and to investigate
further the increase in neuronal death induced by ethanol
withdrawal, we also performed western blot analyses of the
NMDA receptor subunits (figure 2). Concordant with qRT-PCR
results, GluN2A subunit levels decreased during ethanol with-
drawal (figure 2B) (P,0.01), whereas GluN1 (figure 2A) and
GluN2B (figure 2C) levels remained unaffected.
Figure 1. Ethanol withdrawal increases by 40% the sensitivity of neurons to excitotoxic injuries induced by NMDA (10 mM, 24 h) in
cultured cortical neurons. (A) Phase-contrast photomicrographs show representative fields in the indicated conditions (Control, neurons not
exposed to ethanol; EW, ethanol-withdrawn neurons). (B) Quantification of neuronal death. Values are means 6 SEM (n=17–20 wells/condition; N=5
plates). Data were assessed by ANOVA test followed by Fisher’s PLSD test (* P,0.05; *** P,0.001).
doi:10.1371/journal.pone.0023690.g001
Table 1. Ethanol withdrawal (EW) decreases GluN2A mRNA
levels.
CONTROL EW
GluN1 100615.5 75.5611.2
GluN2A 100612.8 56.266.2 *
GluN2B 100615.2 73.9613.3
CB1 100628.5 205.4645.5 a
FAAH 100615.7 88.8610.0
Levels of mRNA transcripts (measured by quantitative PCR) for the N-methyl-D-
aspartate (NMDA) receptor subunits, CB1 receptors, and FAAH enzyme in
cultured cortical neurons in control conditions (neurons not exposed to
ethanol) or during ethanol withdrawal (EW group). Values are normalized to b-
actin gene and expressed as percentages over control data (n=3–4 samples/
group; means 6 SEM). Data were assessed by the Student’s t-test (* P,0.05 vs.
control; a, p=0.097 vs. control).
doi:10.1371/journal.pone.0023690.t001
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viability during ethanol withdrawal
We wanted to test the potential anti-excitotoxic effects of the
cannabinoid agonist HU-210 in control or ethanol-withdrawn
cultured cortical neurons. Schemes of the different treatments are
shown in figures 3A and 4A. HU-210 was added to cell cultures
acutely (only during ethanol withdrawal) (figure 3B) or chronically
(both during the ethanol exposure period and during ethanol
withdrawal) (figure 4B). In both cases, the addition of HU-210
induced a significant protection against NMDA-induced cell death
(36% -P,0.05- and 61% -P,0.01- respectively). This effect was
specific of the withdrawal situation since no neuroprotection by
HU-210 was observed in control (not exposed to ethanol) neurons.
By contrast, the administration of the CB1 antagonist rimonabant
(both acutely -figure 3C- and chronically -figure 4C-) provoked a
significant increase (+56% and +49% respectively, P,0.05) in
NMDA-induced cell death in ethanol-withdrawn neurons. More-
over, the chronic administration of rimonabant to control (not
exposed to ethanol) neurons also tended to increase NMDA-
induced cell death (+33%; p=0.0551) (figure 4C), thus suggesting
that, in contrast to the effects of HU-210, the deleterious effects of
rimonabant were also operative in cultured neurons that were
never exposed to ethanol.
The stimulation of the endocannabinoid system reduces
NMDA-stimulated calcium influx in ethanol-withdrawn
neurons
In order to explain the neuroprotective effect of the cannabinoid
agonist HU-210 and the enhanced neurotoxicity found with
rimonabant in ethanol-withdrawn neurons, we performed single
cell calcium videomicroscopy analysis in ethanol-withdrawn
neurons acutely incubated with vehicle (DMSO), HU-210
(1 mM) or rimonabant (1 mM). Representative curves of calcium
influx for each experiment are shown in figures 5A, 5B and 5C.
We observed a significant decrease (224%; P,0.001) in NMDA-
evoked Ca
2+ influx after incubation with HU-210 (figure 5E) in
ethanol-withdrawn neurons. This supports the idea that the
beneficial effects on cell viability provoked by HU-210 could be
related to a reduction of calcium entry through activated NMDA
receptors, and a subsequent alleviation of calcium-dependent
deleterious pathways. Incubation with vehicle (DMSO) (figure 5D)
or rimonabant (figure 5F) did not produce any modification of
calcium influx. In parallel, we performed the same experiments in
sister control cultures (not exposed to ethanol). The administration
of HU-210, rimonabant or vehicle to control (not exposed to
ethanol) neurons did not have any effect on NMDA-induced Ca
2+
influx (data not shown).
Discussion
In the current study we show, first, that ethanol withdrawal
increases both basal neuronal death and NMDA-stimulated
neuronal death in primary cortical cultures, probably due to a
change in the expression of NMDA receptor subunits. Second, we
evidence for the first time that, during ethanol withdrawal, the
stimulation of the endocannabinoid system protects neurons from
excitotoxic insults, whereas its blockade aggravates neuronal death
induced by NMDA. We show that the neuroprotective effect of
HU-210 during ethanol withdrawal could be explained by a
reduction in Ca
2+ influx through NMDA receptors.
The increase in basal neuronal death found during alcohol
withdrawal, which is concordant with previous results [11],
suggests that chronic alcohol administration and subsequent
withdrawal could decrease the threshold for triggering neurotoxic
processes per se. This hypothesis is compatible with the enhanced
brain damages observed in alcohol-dependent individuals who
experienced successive periods of alcohol consumption, withdraw-
al and relapse [12], as well as in several in vivo experimental
models of alcoholism [2]. In addition, we observed a significant
increase in the sensitivity to NMDA toxicity in withdrawn
neurons. This enhancement of excitotoxicity may reflect the
neuronal adaptation to chronic ethanol exposure and could
contribute to the generation of withdrawal symptoms such as
seizures, pro-convulsive states and might also initiate excitotoxicity
and loss of neurons in certain brain areas during alcohol
withdrawal [12]. It is well accepted nowadays that changes in
the glutamatergic system are one of the principal events
responsible for the neuropathological alterations induced by
chronic alcohol consumption in both laboratory animals and
humans [2]. Our findings support the idea that NMDA receptor
subunit composition changes after chronic alcohol administration
and subsequent withdrawal, since we detected a decrease in
GluN2A expression levels, whereas no changes were detected for
GluN1 or GluN2B. It has been suggested that GluN2A-containing
NMDA receptors promote neuronal survival and would exert a
neuroprotective role against NMDA, while GluN2B-containing
NMDA receptors would mediate neurotoxic processes [13]. If this
Figure 2. Ethanol withdrawal (EW) decreases GluN2A subunit levels. NMDA subunit protein levels measured by Western blot analysis:
GluN2A levels (B) decrease during ethanol withdrawal, whereas the levels of GluN1 (A) and GluN2B (C) remain unaltered. Values are expressed as
percentages over control data for each subunit and are means 6 SEM (n=3–5 samples/condition). Data were assessed by the t-Student’s test
(**P,0.01 vs. control).
doi:10.1371/journal.pone.0023690.g002
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alcohol withdrawal would lead to an imbalance between the
numbers of ‘‘trophic’’ versus ‘‘pro-neurotoxic’’ subunits and could
explain the increase in neuronal death during ethanol withdrawal.
The implication of the endocannabinoid system in alcohol
addiction has been largely studied in the last years. However, most
studies have tried to reduce alcohol reinforcing effects or alcohol
consumption [14], and less attention has been paid to the effects of
cannabinoid stimulation or blockade on the neuropathological
consequences of alcohol dependence and withdrawal. Our study
shows that the stimulation of the endocannabinoid system protects
ethanol-withdrawn neurons from excitotoxic cell death. This
neuroprotection is present when the non-specific cannabinoid
agonist HU-210 is administered both chronically (during ethanol
administration and ethanol withdrawal) and acutely (only during
ethanol withdrawal). Cannabinoid agonists have been proposed as
neuroprotective molecules in several models of acute neuronal
injury and chronic neurodegenerative diseases [15]. Among the
proposed mechanisms of cannabinoid-receptor mediated neuro-
protection, two are particularly relevant for the neurotoxicity
caused by alcohol dependence and withdrawal: the inhibition of
the presynaptic release of glutamate [16] and the inhibition of
NMDA-induced Ca
2+ influx [17]. It appears well-demonstrated
that CB1 receptors are involved in these two neuroprotective
properties of cannabinoid agonists and although HU-210 is a non-
selective cannabinoid agonist, we assume that, in our experiments,
HU-210 preferentially acts through the activation of CB1
receptors because -consistent with the suggestion that CB2
receptors are essentially present in glial cells [18] and considering
the high purity of our neuronal cultures (thanks to the use of an
anti-mitotic agent)- no mRNA encoding for CB2 receptors were
detected in our cultures (data not shown).
As mentioned above, the neuroprotective effect of HU-210
against NMDA was exclusive of alcohol-withdrawn neurons, as it
did not appear in control neurons (not exposed to alcohol). The
absence of neuroprotection of HU-210 against NMDA excitotox-
icity in cultured neurons has been previously reported [19], and
the neuroprotective effect of HU-210 exclusively in ethanol-
withdrawn neurons suggests that the neuroadaptive changes that
occur during alcohol exposure sensitize cells to cannabinoid
neuroprotective mechanisms, perhaps by enhancing CB1 receptor
number and/or their signaling mechanisms. In agreement with
this hypothesis, we found a 2-fold increase in the levels of CB1
receptor transcripts after alcohol cessation, which may explain the
Figure 3. The acute manipulation of the endocannabinoid system influences neuronal viability during ethanol withdrawal. Effects of
the acute activation or blockade of the endocannabinoid signaling on neuronal viability in control (neurons not exposed to ethanol) or ethanol–
withdrawn neurons (EW). (A) Representative scheme of the experimental protocol. (B) The administration of the non-specific cannabinoid agonist HU-
210 (1 mM) during ethanol withdrawal decreases NMDA-induced neuronal death in ethanol-withdrawn neurons. Interestingly, the neuroprotective
effect of HU-210 is specific of alcohol withdrawal situation, since it has no effect on control neurons. (C) The acute administration of the CB1
antagonist rimonabant (1 mM) increases NMDA-induced neuronal death in alcohol-withdrawn neurons. Again, this effect is specific of the withdrawal
situation and rimonabant, when administered acutely, has no effect on control condition. Values are normalized to NMDA and are means 6 SEM
(n=14–18 wells/condition; N=4 plates). Data were analyzed by the ANOVA test followed by the Fisher’s PLSD test (* P,0.05).
doi:10.1371/journal.pone.0023690.g003
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withdrawal and its lack of efficacy in control neurons. To our
knowledge, this is the first time that a neuroprotective role of HU-
210 is found in conditions of alcohol withdrawal. In addition, we
also found that the acute blockade of CB1 receptor-mediated
signals during alcohol withdrawal with rimonabant increased
NMDA-stimulated neuronal death, and again this neurotoxic
effect was absent in control conditions. The data obtained with
rimonabant also support the idea that the effects of HU-210 were
CB1 receptor-mediated, as rimonabant is a selective CB1 receptor
antagonist. The exacerbation of excitotoxin-induced neuronal
death by inhibition of the cannabinoid receptors suggests that
these neurons constitutively produce a cannabinoid receptor
agonist. In accordance with this hypothesis, several authors have
reported an increase in endocannabinoid production (anandamide
and/or 2-arachidonoyl glycerol) after chronic alcohol exposure
both in vitro and in vivo [20–24].
Excessive Ca
2+ influx after the activation of NMDA receptors
triggers neuronal death, whereas the suppression of the Ca
2+ entry
can protect cells from NMDA-induced cytotoxicity [25]. Given the
inhibitory role played by CB1 receptors in Ca
2+ homeostasis, the
effects of CB1 receptor activation or blockade are likely followed
by the corresponding reduction or increase in Ca
2+ influx. Thus,
we performed single cell calcium videomicroscopy analyses to
determine the NMDA-evoked Ca
2+ influx after the incubation
with HU-210 or rimonabant. Consistent with its neuroprotective
effect, the addition of HU-210 to alcohol-withdrawn neurons
reduced NMDA-evoked Ca
2+ influx. This effect was observed only
in ethanol-withdrawn neurons, and not in control neurons (not
exposed to ethanol; data not shown), in concordance with the
results obtained in the excitotoxicity experiments. The addition of
rimonabant to ethanol-withdrawn neurons, however, did not
modify Ca
2+ influx. Our data are supported by previous studies
that described a modulation of NMDA-induced Ca
2+ influx by
CB1 agonists in different brain structures and through different
mechanisms, although these studies were not conducted in
conditions of alcohol withdrawal [17] [26].
In our study, the blockade of the endocannabinoid system with
the CB1 antagonist rimonabant (both acutely and chronically)
increased excitotoxic neuronal death in ethanol-withdrawn
neurons. Moreover, the chronic blockade of the endocannabinoid
system exacerbated excitotoxicity not only in ethanol-withdrawn
neurons but also in control neurons (not exposed to ethanol). This
suggests that the pharmacological blockade of the endocannabi-
noid transmission, especially during alcohol withdrawal, is highly
counterproductive due to its ability to aggravate NMDA-
Figure 4. The chronic manipulation of the endocannabinoid system influences neuronal viability during ethanol withdrawal. Effects
of the chronic activation or blockade of the endocannabinoid signaling on neuronal viability in control (neurons not exposed to ethanol) or ethanol–
withdrawn neurons (EW). (A) Representative scheme of the experimental protocol. (B) The chronic administration of the non-specific cannabinoid
agonist HU-210 (1 mM) decreases NMDA-induced neuronal death during ethanol withdrawal. The neuroprotective effect of HU-210 is specific of
ethanol withdrawal situation, since it has no effect on the control condition. (C) The chronic administration of the CB1 antagonist rimonabant (1 mM)
increases neuronal death. Moreover, the long-term administration of rimonabant tends to be neurotoxic not only for ethanol-withdrawn neurons but
also for control neurons. Values are normalized to NMDA and are means 6 SEM (n=6–16 wells/condition; N=3–4 plates). Data were analyzed by the
ANOVA test followed by the Fisher’s PLSD test. (*P,0.05; ** P,0.01; a, p=0.0551).
doi:10.1371/journal.pone.0023690.g004
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ments derived from its extrapolation to the in vivo situation.
Increases in endocannabinoid levels have been described both in
vivo and in vitro after acute [27] and more strikingly after chronic
alcohol exposure [20] [22] [28], possibly in a cellular attempt to
reduce damages due to alcohol [20] [22]. We can thus hypothesize
that chronic CB1 receptor blockade, especially during alcohol
exposure and withdrawal increases the sensibility to NMDA-
induced cytotoxicity, which is concordant with the protective
function assigned to the endocannabinoid generation in the above-
mentioned studies. In any case, further experiments are needed to
determine more precisely the cause of the deleterious effect of
rimonabant during alcohol withdrawal.
Rimonabant has been proposed as a promising drug for the
treatment of alcoholism, with positive effects on alcohol intake in
laboratory animals under several administration protocols [29].
However, these preclinical data were not reproduced in the two
clinical studies conducted to date with rimonabant (one in alcohol-
dependent individuals and one in non treatment-seeking heavy
alcohol drinkers) [30–31]. Moreover, further studies on the
therapeutic potential of rimonabant in the treatment of alcohol
dependence are apparently hindered, since the recent decision of
the discontinuation of all clinical trials with this CB1 antagonist
due to the occurrence of some psychiatric adverse effects. The
results of the present work point in the same direction showing, for
the first time, the potential neurotoxic effect of chronic
administration of rimonabant in an in vitro model of alcohol
withdrawal. It is also possible that the reason why rimonabant
aggravated the deleterious effects of alcohol withdrawal in our in
vitro model is related to its inverse agonist properties. If this is the
case, it is likely that we will need the development of novel neutral
antagonists, with no inverse agonist activity, that may be used
efficaciously for treating alcohol craving with no additional
neurotoxic effects.
In summary, these observations show, for the first time, that the
stimulation of the endocannabinoid system could be protective
against the hyperexcitability developed during alcohol withdrawal.
By contrast, the blockade of the endocannabinoid system seems to
be highly counterproductive during alcohol withdrawal due the
ability of rimonabant to exacerbate NMDA-induced excitotoxic-
ity.
Materials and Methods
Materials
NMDA and HU-210 were purchased from Tocris (Bristol, UK).
Rimonabant was generously provided by Sanofi-Aventis (Mon-
tpellier, France). Dulbecco’s modified Eagle’s medium (DMEM),
poly-D-lysine, laminin, glutamine, cytosine b-D-arabinoside, were
purchased from Sigma-Aldrich (L’Isle d’Abeau, France).
Ethics Statement
All animal procedures were performed in accordance with
French (act no. 87-848; Ministe `re de l’Agriculture et de la Fore ˆt)
and European Communities Council Directives of November 24,
1986 (86/609/EEC) guidelines for the care and use of laboratory
Figure 5. The stimulation of the endocannabinoid system reduces NMDA-stimulated calcium influx in ethanol-withdrawn neurons.
(A, B, C) Representative recordings of single-cell calcium videomicroscopy for each experiment. A 30 sec exposure to NMDA (50 mM) produced a rapid
calcium influx, which recovered over the following 2 min (before). (E) After the incubation (10 min) with the non-specific CB1 agonist HU-210 (1 mM),
Ca
2+ influx (induced by NMDA application) is significantly decreased in comparison to the stimulation before. Incubation (10 min) with DMSO (D) or
rimonabant (1 mM) (F) does not modify NMDA-stimulated calcium influx. Values are expressed as % vs. before NMDA-stimulation 6 SEM (N=3–4; n
(cell number) .60 cells). Data were analyzed by the t Student’s test. (***P,0.001).
doi:10.1371/journal.pone.0023690.g005
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the experimenter (personal license number 14-65) were accredited
by the Direction De ´partementale des Services Ve ´te ´rinaires. Swiss
mice were maintained on a 12:12 h light/dark cycle, with ad
libitum access to food and water. In agreement with the rules of
humane killing on the day of use, pregnant mice were euthanized
by anaesthetic overdose (carbon dioxide). Comite ´ d’Ethique
NOrmandie en Matie `re d’EXpe ´rimentation Animale’’ (CENO-
MEXA) certifies that this study did not require referral to the
regional ethics committee.
Neuronal cultures
Neuronal cultures were prepared from Swiss mouse embryos
(embryonic day 15–16) as described earlier [32]. Cortices were
dissected and dissociated in DMEM, and plated on 24-well plates
earlier coated with poly-D-lysine (0.1 mg/ml) and laminin
(0.02 mg/ml). Cells were cultured in DMEM supplemented with
5% foetal bovine serum (Invitrogen, Cergy Pontoise, France), 5%
horse serum (Invitrogen, Cergy Pontoise, France) and 2 mM
glutamine. Cultures were maintained at 37uC in a humidified 5%
CO2 atmosphere. Cytosine b-D-arabinoside (Ara C, 10 mM) was
added after 3 days in vitro (DIV) to inhibit glial proliferation. All
treatments were performed after 8 and/or 11–13 DIV as required.
Ethanol and cannabinoid treatments
Following the model described by Nagy et al. [9], ethanol
(100 mM in DMEM) was daily administered to cell cultures from
DIV8during3 consecutivedays.Nomore ethanolwasaddedtothe
culture cell medium afterwards to induce ethanol withdrawal (DIV
11–13). Cannabinoid compounds were dissolved in 100% dimethyl
sulfoxide (DMSO) as a 10 mM stock and diluted with DMEM to
their final concentrations. HU-210 (1 mM) or rimonabant (1 mM)
were added to cell cultures chronically (from DIV 8 until DIV 13),
or only during the ethanol withdrawal period (DIV 11–13).
Excitotoxic challenges (see next section) were always performed at
DIV12 and neuronaldeath measured at DIV 13. Protein and RNA
samples were extracted from separate series of plates at DIV 12.
Induction of excitotoxicity and determination of cell
viability
Excitotoxicity was induced by exposure to NMDA (10 mM) in
serum-free DMEM supplemented with 10 mM of glycine for 24 h.
This was always done at DIV 12 and neuronal death was
quantified 24 h later (DIV 13) by measurement of the activity of
lactate dehydrogenase (LDH) released from damaged cells into the
bathing medium with a cytotoxicity detection kit (Roche
Diagnostics, Mannheim, Germany). The LDH level correspond-
ing to the maximal neuronal death was determined in sister
cultures exposed to 200 mM NMDA (LDHmax). Background
LDH levels were determined in sister cultures subjected to control
washes (LDHmin). Experimental values were measured after
subtracting LDHmin and then normalized to LDHmax–LDHmin
to express the results as a percentage of neuronal death.
Immunoblotting
Ice-cold TNT buffer (50 mM Tris-HCl pH 7.4; 150 mM NaCl;
0.5% Triton X-100)-dissociated cells were centrifuged (10,000 g,
4uC, 15 min), and protein content assessed by the BCA method
(Pierce, France). Protein samples (20 mg) were resolved on a 10%
SDS PAGE and transferred onto a polyvinylidene difluoride
membrane. Membranes were blocked with 5% dried milk in Tris-
buffered saline (TBS, 10 mM Tris; 200 mM NaCl; pH 7.4)
containing0.05%Tween-20and incubated withprimaryantibodies
(GluN1, GluN2A, GluN2B, 1:200; all from Santa Cruz, Germany).
After incubation with the corresponding secondary peroxidase
conjugated antibody (1:5000; Sigma Aldrich, France), proteins were
visualized with an enhanced chemiluminescence ECL Plus
immunoblotting detection system (Perkin Elmer-NEN, Paris,
France).
Quantitative real-time RT-PCR
Total RNAs were extracted from cultured cells by using the
NucleoSpin RNA II kit from Macherey-Nagel, according to the
manufacturer’s instructions and eluted with RNase free water.
One microgram of total RNAs from each sample was reverse
transcribed using the Promega RT system (Promega, Charbon-
nieres, France; reverse transcription: 42uC for 1 h). Two primers
were designed for each gene using the Beacon Designer software
(Bio-Rad, Marnes-la-Coquette, France). Primer alignments stud-
ied with the BLAST database ensured the specificity of primers
(see sequences for primers used in Table 2). PCR solutions were
prepared with RNase-free water containing primers and IQ SYBR
Green Supermix (Bio-Rad). For PCR amplification, 20 ml of mix
were added to 5 ml of reverse transcription reaction diluted earlier
(1:20). Two negative controls were performed during each
experiment. In the first control, we used samples without reverse
transcription as a template to control contamination of RNA with
genomic DNA. In the second control, we used RNase-free water
instead of cDNA to prove that qPCR mixes were not con-
taminated with DNA. Assays were run in triplicate on the iCycler
iQ real-time PCR detection system (Bio-Rad). The amplification
conditions were as follows: Hot Goldstar enzyme activation, 95uC
for 3 minutes; 50 cycles of PCR at 95uC, 15 sec and 60uC, 1 min.
The levels of expression of interest gene were computed as follows:
relative mRNA expression=2
2(Ct of gene of interest) where Ct is the
threshold cycle value.
Single cell calcium videomicroscopy analysis
Primary cultures of cortical neurons (control -not exposed to
alcohol- or ethanol-withdrawn) were loaded in the presence of
Table 2. Sequences of primers used for quantitative PCR.
forward reverse
NMDA GluN1 CTCTAGCCAGGTCTACGCTATCC GACGGGGATTCTGTAGAAGCCA
GluN2A ACATCCACGTTCTTCCAGTTTGG GACATGCCAGTCATAGTCCTGC
GluN2B CCAGAGTGAGAGATGGGATTGC TGGGCTCAGGGATGAAACTGT
CB1 GTGTGCTGTTGCTGTTCATTGTG CCTTGCCATCTTCTGAGGTGTG
FAAH ATGAACCCGTGGAAGCCCTC CGCCGATGTCAGTGCCTAAAC
doi:10.1371/journal.pone.0023690.t002
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plus 0.1% pluronic F-127 (30 min, at 37uC; Molecular Probes,
Leiden, the Netherlands) and incubated for an additional 30 min
in HEPES-buffered saline solution. Experiments were performed
at 22uC on the stage of a Nikon Eclipse inverted microscope
equipped with a 75W Xenon lamp and a Nikon 640, 1.3
numerical aperture epifluorescence oil-immersion objective. Fura-
2 (excitation: 340 and 380 nm, emission: 510 nm) ratio images
were acquired with a CCD camera (Princeton Instrument,
Trenton, NJ, USA), and digitized using Metafluor 4.11 software
(Universal Imaging Corporation, Cherter, PA, USA). Each
experiment consisted in measuring NMDA-stimulated Ca
2+ entry
(25 mM NMDA) after 10 min incubation with HU-210 (1 mM),
rimonabant (1 mM) or vehicle (DMSO). For each plate, basal
NMDA-stimulated calcium entry was measured prior to incuba-
tions.
Statistical analyses
All data were assessed by Student’s t-test or one-way analysis of
variance, as required. In the case of using analysis of variance, we
used the Fisher’s PLSD test as post-hoc test. All statistical analyses
were done using the Statview software.
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